Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hBMMSC for Autoimmune Pulmonary Alveolar Proteinosis
NCT06111846Phase 2Active, not recruiting
- Sponsor
- Jiuzhitang Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 2, open-label trial in autoimmune pulmonary alveolar proteinosis (aPAP) (3 arms), sponsored by Jiuzhitang Co., Ltd. Primary endpoint: Alveolar-arterial difference in oxygen tension at 24 weeks. Started Dec 2023; status: active, not recruiting.
02
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on NCT06111846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06111846.